by Hilma Biocare
Triple GIP/GLP-1/Glucagon agonist. Next-generation metabolic research compound.
In stock
Pay with Bitcoin or USDT (TRC-20) on this site, or contact a representative for a card or bank payment link. Free EU shipping over €250.
Batch certificate of analysis available on request via Telegram or the contact form.
Retatrutide (LY3437943, Eli Lilly) is the first triple incretin agonist in advanced clinical research — simultaneously activating GIP (glucose-dependent insulinotropic polypeptide), GLP-1 and glucagon receptors. This tri-agonist profile addresses obesity and metabolic disease from three complementary angles: GLP-1R reduces appetite and gastric emptying; GIPR amplifies postprandial insulin and synergizes with GLP-1 for superior caloric deficit; glucagon receptor activation directly increases energy expenditure and hepatic fat oxidation. Phase 2 SURMOUNT data (2023) reported up to 24.2% mean body weight reduction at 48 weeks — the largest ever recorded for a pharmacological agent in a clinical trial.
Currently in Phase 3. Lyophilized powder, Janoshik-verified 98.5% purity. For research use only.
Weight Loss & GLP-1
The top 10 most-researched peptides of 2025 ranked by published study volume, mechanistic depth, and research versatility. Covering BPC-157, TB-500, semaglutide, ipamorelin, SS-31, retatrutide, PT-141, CJC-1295, tirzepatide, and NAD+ precursor peptides with their current research status.
6 min read
Weight Loss & GLP-1
GLP-1 receptor agonist research is evolving rapidly beyond injectable semaglutide: oral formulations, triple agonists (GLP-1/GIP/glucagon), CNS-targeted analogs, and organ-protective applications. Research guide to the next-generation GLP-1 pipeline and the mechanistic frontiers being explored in 2025–2026.
6 min read
Peptides & Recovery
Semaglutide-based metabolic research protocols use diet-induced obesity (DIO) rodent models to study GLP-1R-mediated weight loss, glycemic improvement, and lipid remodeling. Guide to the semaglutide DIO research stack — compound selection, protocol design, dose escalation, and endpoints.
4 min read
Research use only. All products are sold strictly for in-vitro and laboratory research. Not for human consumption, veterinary use, diagnosis, treatment or prevention of any disease. Must be handled by qualified professionals in a controlled laboratory setting. JuicedPharma makes no therapeutic or medical claims about this compound.
ZPHC
Retatrutide 10mg (5×2mg) lyophilized by ZPHC. Triple GIP/GLP-1/Glucagon agonist.
99%+· ZPHC
ZPHC
Retatrutide 15mg single vial by ZPHC. Starter dose for triple agonist research.
99%+· ZPHC
ZPHC
Retatrutide 20mg kit (5×4mg) by ZPHC. GIP/GLP-1/Glucagon triple agonist.
99%+· ZPHC
ZPHC
Retatrutide 30mg premixed AQ auto-injector pen by ZPHC. Ready-to-use.
99%+· ZPHC
Resellers, laboratories and publishers: apply for partner pricing, volume terms and a dedicated representative.
Research use only. All products are sold strictly for in-vitro and laboratory research. Not for human consumption, veterinary use, diagnosis, treatment or prevention of any disease. Products sold by JuicedPharma are not medicines. By ordering you confirm you are a qualified person buying for research in compliance with applicable regulations. Full disclaimer